ACAD
HealthcareACADIA Pharmaceuticals Inc.
$26.15
$-0.14 (-0.53%)
Jan 5, 2026
Price History (1Y)
Analysis
ACADIA Pharmaceuticals Inc. operates within the healthcare sector and biotechnology industry, with a market capitalization of $4.42B, annual revenue of $1.05B, and 653 employees. The company's financial health indicates moderate profitability, with gross margin at 59.0%, operating margin at 12.8%, and profit margin at 24.9%. Returns on equity and assets are 35.0% and 5.1%, respectively, while the debt-to-equity ratio is 5.97. The balance sheet also shows a cash position of $847.02M against debt of $54.81M. The company's valuation context features a P/E ratio (TTM) of 16.98 and forward P/E of 32.10, with revenue growth at 11.3% year-over-year and earnings growth at 112.8%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
Visit website →Key Statistics
- Market Cap
- $4.42B
- P/E Ratio
- 16.98
- 52-Week High
- $28.35
- 52-Week Low
- $13.40
- Avg Volume
- 1.66M
- Beta
- 0.68
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 653